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Abstract.
Purpose: Fifty percent of patients with Multiple Sclerosis (MS) are estimated to have cognitive impairments leading to consid-
erable decline in productivity and quality of life. Cognitive intervention has been considered to complement pharmacological
treatments. However, a lack of agreement concerning the efficacy of cognitive interventions in MS still exists. A systematic
review and meta-analysis was conducted to assess the effects of cognitive interventions in MS.
Methods: To overcome limitations of previous meta-analyses, several databases were searched only for Randomized Clinical
Trials (RCTs) with low risk of bias.
Results: Five studies (total of 139 participants) met our eligibility criteria. Although good completion and adherence rates were
evident, we found no evidence of intervention effects on cognition or mood in post-intervention or follow-up assessments.
Conclusions: This is the first meta-analysis assessing the effects of cognitive intervention in MS including only RCTs with
comparable conditions. Research regarding efficacy, cost-effectiveness and feasibility is still in its infancy. Caution is advised
when interpreting these results due to the small number of RCTs meeting the inclusion criteria. Considering the costs of disease,
good completion and adherence rates of this approach, further research is warranted. Recommendations concerning improved
research practices in the field are presented as well.
Keywords: Rehabilitation, multiple sclerosis, systematic review, meta-analysis, feasibility
1. Introduction
Early studies have reported that 40% of individuals
afflicted by Multiple Sclerosis (MS) suffer from cogni-
∗Corresponding author: Rosana Magalha˜es, Laborato´rio de Neu-
ropsicofisiologia, Escola de Psicologia, Universidade do Minho -
Campus de Gualtar, 4710-057 Braga, Portugal. Tel.: +351 253
601398; Fax: +351 253 604224; E-mail: rosana.magalhaes@
psi.uminho.pt.
tive deficits (Rao et al., 1991), with more recent studies
increasing this estimate to 50% (Benedict et al., 2006).
Cognitive impairments are often identified in the early
phases of the disease and frequently progress over time
(Amato et al., 2001). In people with MS, cognitive
impairments often lead to disruptions in work, daily
activities, family, interpersonal life (DeLuca, 2006),
and an overall decline in Quality of Life (QoL) (Grima
et al., 2000).
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Commonly impaired cognitive functions include
learning and memory (between 40 to 60% of patients)
(DeLuca et al., 1994); divided attention (McCarthy
et al., 2005); working memory (Rao et al., 1993);
executive functioning (mainly on concept-formation,
planning, and organization skills) (Brassington and
Marsh, 1998); and speed of processing (Chiaraval-
loti and DeLuca, 2008). Additionally, a large body
of literature unveiled global intellectual functioning
(Brassington and Marsh, 1998) and language skills
(DeLuca, 2006) to be largely preserved in people with
MS. Recent research has shown deficits in speed of
processing to be the primary cognitive deficit in MS
(DeLuca et al., 2004), possibly also contributing to
other cognitive deficits such as learning and memory
(Chiaravalloti et al., 2013).
Pharmacological treatments, including drugs
such as donepezil, memantine, rivastigmine,
methylphenidate, and l-amphetamine have been
examined for their impact on memory, information
processing and divided attention (Amato et al.,
2013; He et al., 2011). While some positive results
have been noted (Krupp et al., 2004) they were
often followed by a failure to replicate the results
(Amato et al., 2013; Krupp et al., 2011), therefore the
impact of such treatments remains to be debatable
(He et al., 2011). One exception is L-amphetamine
sulfate, which has shown some potential in improving
learning and memory in MS (Sumowski et al., 2011).
Nevertheless, more research is needed to assess the
efficacy of pharmacological agents in enhancing
Multiple Sclerosis-related cognitive impairments
(Morrow et al., 2009).
Currently, non-pharmacological treatments for cog-
nitive impairments in MS are being developed.
Because of the encouraging results with healthy aging
populations (Lustig et al., 2009) and several neurolog-
ical diseases such as Alzheimer’s disease (Alves et al.,
2013), cognitive interventions have also been tested
for cognitive impairment in MS. Cognitive interven-
tions often include cognitive training and rehabilitation
focusing on one (Chiaravalloti et al., 2005; Vogt et al.,
2009) or several domains of cognition (Brissart et al.,
2010; Stuifbergen et al., 2012). Interventions may be
delivered by a training software (Fink et al., 2010;
Solari et al., 2004; Stuifbergen et al., 2012; Tesar et al.,
2005) or treatment manuals, using pencil and paper
approaches to teach patients the use of internal memory
aids and compensatory strategies (Chiaravalloti et al.,
2005; das Nair and Lincoln, 2012).
Some studies have also noted an improvement in
emotional functioning following cognitive rehabilita-
tion (Brenk et al., 2008; Mattioli et al., 2010) while
others found no effect of cognitive intervention on
patients’ quality of life (Hildebrandt et al., 2007; Lin-
coln et al., 2002; Mattioli et al., 2010) and cognition
(Lincoln et al., 2002; Solari et al., 2004).
Considering these mixed results, previous meta-
analyses (Rosti-Otajarvi and Hamalainen, 2011;
Thomas, et al., 2006) examined the efficacy of sev-
eral non-pharmacological interventions in MS for
cognitive impairments, depression, anxiety and cop-
ing strategies. However, combining different types of
interventions and study designs in the same meta-
analysis can lead to misleading conclusions concerning
the efficacy of cognitive interventions. For exam-
ple, a quantitative meta-analysis (das Nair et al.,
2012) study combined different types of memory out-
comes (memory for word list, story memory, and
memory scales/composites) into the same memory
comparison and found lack of evidence concerning the
efficacy of cognitive interventions. In a more recent
review paper (Amato et al., 2013), no quantitative
results were provided, postponing the emergence of
definite conclusions. Furthermore, only few studies
included longitudinal assessments and, when consid-
ered in previous meta-analysis, no significant results
have been found at the follow-up moments (das
Nair et al., 2012; Rosti-Otajarvi and Hamalainen,
2011).
In order to overcome the limitations of previous
meta-analyses, the present review compares studies
including only Randomized Controlled Trials at low
risk of bias for randomization, adherence to protocol
and attrition as well as comparable interventions.
2. Methods
2.1. Data sources and eligibility criteria
The following databases were searched for Random-
ized Controlled Trials of cognitive interventions in MS
from inception to April 4th, 2013: PubMed, Psych-
INFO and EMBASE. The Cochrane Library (Cochrane
CENTRAL Register of Controlled Trials and Cochrane
Reviews) was searched in addition to reference lists
from four major reviews (das Nair et al., 2012; O’Brien
et al., 2008; Rosti-Otajarvi & Hamalainen, 2011;
Thomas, Thomas et al., 2006). No language limitations
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Fig. 1. Flow diagram.
Table 1
Search expressions for PubMed
Search terms used for Randomized Controlled Trials of cognitive interventions in MS:
(Memory OR Working memory OR Attention OR Concentration OR “Information processing” OR “speed of processing”
OR “Executive Functioning” OR “executive functions” OR Reasoning OR Language OR “Verbal fluency” OR
Visuo-spatial OR Visuoconstructive OR visuospatial OR Cognitive OR Cognition OR Neurocognitive OR
Neuropsychological OR Compensatory OR Remediation OR remediative OR Restorative OR restoration OR Learning
OR Cognitive-motor) AND (Intervention OR Stimulation OR Rehabilitation OR Program OR Programme OR Training
OR Retraining) AND (“multiple sclerosis” OR “demyelinating disease” OR “acute disseminated encephalomyelitis” OR
“encephalomyelitis disseminate” OR “disseminated sclerosis” OR “demyelinating autoimmune disease”) AND
(“randomized controlled trial” OR “randomized clinical trial” OR “randomized controlled study” OR “randomized
controlled trial” OR “randomized clinical trial” OR “randomized controlled study” OR “randomized pilot study” OR
“randomized pilot study” OR “controlled study”)
Search terms used in the PubMed for costs or cost-effectiveness of cognitive intervention in Multiple Sclerosis: multiple
sclerosis, cognitive, cognition, cost, medical care, expenditures, medical care expenses, cost-effectiveness and cost benefit.
were applied. See Fig. 1 Flow diagram (Moher et al.,
2009) and Table 1.
Two authors (RM and JA) independently applied
these inclusion criteria to abstracts and full-texts:
1. Randomized Controlled Trials only;
2. Patients with confirmed Multiple Sclerosis diag-
nosis, using accepted standardized neurological
criteria (e.g., McDonald criteria of 2001, revi-
sions of 2005 and 2010 or Poser’s 1983 criteria);
3. Patients with MS that received cognitive inter-
vention;
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4. Intervention delivered by trained techni-
cians/research team member;
5. Mock intervention employed for comparison;
6. Pre- and post-assessment (sufficient data to cal-
culate effect size).
The following exclusion criteria were applied:
1. Non-randomized studies;
2. Pharmacological trials;
3. Diagnosis other than Multiple Sclerosis;
4. Interventions such as “Neuropsychological”
counseling, cognitive behavioral therapy (CBT)
or educational therapy (techniques with intent to
modify behavior, to manage stress and teaching
of Psychoeducation related to the disease);
5. Conditions of cognitive intervention dissimilar
in frequency of intervention sessions (2 times
a week vs. 3 times a week, etc.); duration of
the intervention program (4 weeks vs. 6 weeks,
etc.); duration of intervention sessions (50 min.
vs. 90 min., etc.); and contact with the therapist
(one group meeting with therapists and being part
of a program vs. other group waiting to be con-
tacted);
6. Interventions comparing MS groups with healthy
control groups.
None of the retrieved studies reported costs or
cost-effectiveness for which an additional search was
undertaken in PubMed (search terms in Table 1).
For the feasibility analysis we recorded the num-
ber of dropouts after randomization in each study, the
reasons for dropping out, and the number of missed ses-
sions. We calculated the completion rate (percentage
of people who completed the intervention programs)
and adherence rate for each group (number of ses-
sions attended divided by the total number of program
sessions).
2.2. Data extraction and analysis
In order to establish the validity of eligible ran-
domized controlled trials, two authors (RM and JA)
independently reviewed the articles and assessed the
randomization and concealment of allocation, blinding
of patients, personnel and outcome assessment, attri-
tion and reporting bias. For data analyses, data and risk
of bias scores were entered into the Cochrane Collab-
oration’s Review Manager Software Version 5.2.3 for
Windows (RevMan, 2012).
All available information from studies on cognition,
mood, psychomotor, subjective measures of cogni-
tive functions, and quality of life were collected.
Studies were excluded if they lacked test scales or
units.
Mean scores, standard deviations of post-treatment
assessments and number of patients per group at
randomization was recorded. When available, mean
change scores from pre- to post-treatment were
recorded instead and data collected for the longest
follow-up interval. When heterogeneity was low (i.e.,
I2 < 50), continuous data were analyzed by mean dif-
ferences using the fixed effects model (with 95%
confidence intervals, CI).
Given that neuropsychological test outcomes var-
ied across studies, they were grouped into typical
domains. When studies measured a domain utiliz-
ing different measures, standardized mean differences
were employed. By default, the software considered a
lower value as a better outcome, therefore the default
setting was used for measuring mood or memory
complains.
Forest plots were then generated for each domain.
Visual inspection of graphs and the I2 Index was used
to assess heterogeneity.
3. Results
3.1. Included studies
The search identified 113 studies (after removal
of duplicates). After refining the search, 82 articles
were excluded because they were either review, non-
interventional or pharmacological treatment studies.
Although 31 potential candidate articles were con-
sidered for the meta-analysis, after full-texts were
inspected several studies had to be excluded if con-
trol groups were missing; the comparison group was
composed of healthy subjects; compared interven-
tions were not comparable, patients were not randomly
assigned; intervention(s) focused on domains other
than cognition; or authors could not provide necessary
data (Solari et al., 2004).
Five articles (Cerasa et al., 2013; Chiaravalloti et al.,
2005; Chiaravalloti et al., 2012; das Nair & Lincoln,
2012; Mendozzi et al., 1998) with low risk of bias met
our inclusion criteria and were selected for quantita-
tive analysis (Fig. 1 Flow diagram), summing up 139
participants in total.
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Fig. 2. Risk of bias summary graph. Rows correspond to the included articles in the meta-analysis and each column corresponds to the parameters
of the risk of bias assessment. Each circle represents the risk of bias assessment of a particular parameter in each study.
Risk of bias was independently assessed by two
authors (RM and JA). Risk of bias summary graph is
displayed in Fig. 2.
Further characteristics of included studies and the
respective outcome measures are presented in Table 2.
3.2. Cognitive intervention efﬁcacy analysis
Studies employed a vast diversity of measures/tests
of cognitive outcomes such as memory, speed of pro-
cessing and mood. Therefore, ten comparisons were
constructed: overall memory functioning, episodic
verbal memory (including wordlist total learning;
immediate memory of story recall; and delayed recall
of wordlist), working memory, visual memory, subjec-
tive memory (immediate and long-term effects), speed
of processing, depressive (immediate and long-term
effects) and anxiety symptoms/complaints.
Results of cognitive intervention effects are shown
in Table 3 and in Fig. 3.
628 R. Magalha˜es et al. / Are cognitive interventions for Multiple Sclerosis effective and feasible?
Table 2
Descriptions/Characteristics of the included studies
Study
Sample details (diagnosis,
clinical course, physical and
cognitive status)
Intervention Condition (n) Comparison Condition (n) Measures/Outcomes
(Cerasa et al., 2013) Clinically
definite RRMS.
Computer-assisted training
(software RehaCom) of several
attention ability and
information processing tasks
(n = 13)
Computerized tests of visuomotor
coordination tasks, using an
in-house software (n = 13)
Brief repeatable battery (BRB)
26 RRMS (12 sessions of 1-hour, twice a
week, 6 weeks)
(12 sessions of 1-hour, twice a
week, 6 weeks)
Trail Making Test A, B
Patients with Expanded
Disability Status Scale (EDSS)
score ranging from 0 to 4.
Mini-Mental State Examination
Patients “with predominant
deficits in either attention
and/or information processing
speed, working memory, and/or
executive functioning” but
without severe cognitive
impairment (patients who
failed a maximum of 2 tests).
Beck Depression Inventory
State-Trait Anxiety Inventory
(Y1, Y2)
(Chiaravalloti et al., 2012)
Clinically definite
Program using modified Story
Memory Technique (mSMT)
(n = 8)
Control group included tasks
such as reading the same stories
and answering questions (n = 8)
California Verbal Learning Test)
Multiple Sclerosis (2001
McDonald’s criteria). 11/16
RRMS
(10 sessions of 45–60 min, twice
a week, 5 weeks)
(10 sessions of 45–60 min, twice
a week, 5 weeks)
Prose Memory test (Memory
Assessment Scale)
Patients’ physical disease
severity was measured by the
Ambulation Index
(experimental
group = 2.13 ± 1.73; control
group = 3.75 ± 1.39).
Rivermead Total Profile Score
All patients were determined to
have impaired verbal new
learning (as measured by
performance at an adaptation
of the Buschke Selective
Reminding Test).
Judgment Line Orientation test
Symbol Digit Modalities Test
Memory Functioning
Questionnaire
State-Trait Anxiety Inventory
(Y1, Y2)
Chicago Multidimensional
Depression Inventory
Neuroimaging (cerebral
activation during fMRI tasks)
(das Nair and Lincoln, 2012)
Diagnosis was verified by
hospital or general practitioner
Restitution program (n = 17): use
of internal memory aids;
exercises to practice encoding
and retrieval and attention
retraining exercises
Compensation program (n = 12):
use of internal and external
memory aids (2 individual + 10
weekly group sessions of
1.5-hour)
Verbal and visual memory tests
29 MS patients (2 individual + 10 weekly group
sessions of 1.5-hour)
Tests for executive abilities,
mood and disability
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Table 2
(Continued)
Study Intervention Condition (n) Comparison Condition (n) Measures / Outcomes
Course of disease not specified.
No information regarding
patients’ disease severity.
Patients included with manifested
memory deficits (defined as an
overall profile score of <1 on
the Rivermead Behavioural
Memory Test – Extended
version).
(Chiaravalloti et al., 2005)
Clinically definite
Program using modified Story
Memory Technique (mSMT)
(n = 14)
Non-specific control tasks such
as such as reading stories,
recalling it and answering
questions about the stories
(n = 14)
Attention, concentration
(baseline)
Multiple Sclerosis (1983 Poser’s
criteria)
(8 sessions of 45-min, twice a
week, for 4 weeks)
(8 sessions of 45-min, twice a
week, for 4 weeks)
Language (baseline)
17 RRMS, 4 PPMS, 7 SPMS Information processing (baseline)
Patients’ physical disease
severity was measured by the
Ambulation Index (range: 0–9:
mean = 2.86 ± 2.66).
Episodic memory
All patients were determined to
have impaired verbal new
learning (as measured by
performance at an adaptation
of the Buschke Selective
Reminding Test).
Emotional functioning
Meta-memory
(Mendozzi et al., 1998) Definite Cognitive Rehabilitation program
(SCRP) to train memory and
attention (n = 20)
Non-specific Cognitive
Rehabilitation program
(NCRP) designed to train
cognitive abilities other than
memory (n = 20) (15 sessions
of 45-min, twice a week, for 8
weeks)
Verbal and visual declarative
memory, recognition memory,
memory span, selective
attention and speed of reaction
Multiple Sclerosis (1983 Poser’s
criteria)
(15 sessions of 45-min, twice a
week, for 8 weeks)
RRMS and SPMS
Patients’ disease severity was
measured with EDSS (SCRP
group = 3.65 ± 2.2); NCRP
group = 4.00 ± 2.1).
“As a whole, our MS sample
showed mild-to-moderate
impairment in all memory,
attention, and reaction tests”
Abbreviations: RRMS, Relapsing Remitting Multiple Sclerosis; SPMS, Secondary Progressive; PPMS, Primary Progressive Multiple Sclerosis.
No significant effects were identified in overall
memory functioning (standardized mean difference,
−0.02; 95% CI, −0.62–0.57); learning wordlists (stan-
dardized mean difference, 0.11; 95% CI, −0.27–0.50);
delayed recall of wordlists (standardized mean differ-
ence, 0.19; 95% CI, −0.44–0.82); immediate memory
in story recall (standardized mean difference, −0.27;
95% CI, −0.80–0.26); working memory (standard-
ized mean difference, 0.28; 95% CI, −0.25–0.81);
visual memory (standardized mean difference, 0.02;
95% CI, −0.49–0.54), subjective memory assess-
ment (standardized mean difference, −0.44; 95% CI,
−0.93–0.05), speed of processing (mean difference,
−0.13; 95% CI, −6.73–6.46), mood (standardized
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Fig. 3. Forest plots. Note: Given that most neuropsychological mea-
sures employ higher scores to indicate better performance, forest plot
labels were adjusted (i.e. inverted) when needed. (a) Negative effect
sizes are interpreted as favoring the experimental group (higher test
scores indicate worse outcome).
mean difference, −0.23; 95% CI, −0.64–0.17), or
anxiety symptoms (mean difference, 95% CI, −3.34;
−8.38–1.71).
Concerning the long-term effects of cognitive inter-
vention, no significant effects were identified in
mood (standardized mean difference, 0.25; 95% CI,
−0.28–0.78) or memory complaints (standardized
mean difference, −0.29; 95% CI, −0.84–0.26).
No evidence of heterogeneity was found (the I2
index was always <50%); (Higgins et al., 2003) except
for visual memory comparison (89%).
3.3. Cost-effectiveness data analysis
The search for costs of cognitive interventions run in
PubMed yielded 25 results. Only four of these studies
assessed costs of different interventions (exercise and
cognitive-behavioral therapy), with three of them being
trial protocols with no available data. Moss-Morris and
colleagues (2012) analyzed the effect of an Internet-
based cognitive behavioral therapy self-management
program for fatigue in MS while presenting only the
costs related to utilized services. They concluded that
the costs were very similar between intervention and
control groups with minimal gains in terms of mea-
sures of quality adjusted life years (QALYs), with no
estimation of costs related to the implementation of the
programs.
3.4. Analysis of feasibility
The completion rate, for the experimental interven-
tion ranged between 92.3% and 100%, and control
intervention between 84.6% and 100%. The adherence
rate was estimated to be 100% (both for the interven-
tion and control groups). See Table 4.
4. Discussion
The present study is the first meta-analysis focus-
ing on cognitive intervention trials at low risk of bias
including active control condition/groups.
From an initial pool of more than one hundred
results, only 5 studies met our eligibility criteria, with
a total of 139 MS patients. Despite the fact that individ-
ual studies showed positive results, when pooled in the
meta-analysis we found no significant effects in any of
the analyzed cognitive or emotional domains, either for
immediate post-intervention or follow-up assessments.
632 R. Magalha˜es et al. / Are cognitive interventions for Multiple Sclerosis effective and feasible?
Ta
bl
e
4
Fe
as
ib
ili
ty
an
al
ys
is
o
fi
nc
lu
de
d
st
ud
ie
s
St
ud
y
D
ro
po
ut
sa
fte
r
ra
n
do
m
iz
at
io
n
Co
m
pl
et
io
n
ra
te
pe
rg
ro
up
R
ea
so
ns
fo
rw
ith
dr
aw
al
N
um
be
ro
fm
iss
ed
in
te
rv
en
tio
ns
A
dh
er
en
ce
ra
te
pe
rg
ro
up
Ce
ra
sa
et
al
.,
20
13
Tw
o
pa
tie
nt
sf
ro
m
th
e
co
n
tr
ol
gr
ou
p;
1
fro
m
th
e
ex
pe
rim
en
ta
lg
ro
up
84
.6
%
fo
rc
o
n
tr
ol
gr
ou
p
D
ec
id
ed
n
o
tt
o
co
n
tin
ue
w
ith
th
e
pr
ot
oc
ol
–
10
0%
in
bo
th
gr
ou
ps
(as
su
me
d)
92
.3
%
fo
rt
he
ex
pe
rim
en
ta
lg
ro
up
Ch
ia
ra
v
al
lo
ti,
W
yl
ie
,
Le
av
itt
,D
el
uc
a,
20
12
0
10
0%
fo
rc
o
n
tr
ol
gr
ou
p
–
0
10
0%
in
bo
th
gr
ou
ps
10
0%
fo
re
x
pe
rim
en
ta
l
gr
ou
p
da
sN
ai
r&
Li
nc
ol
n,
20
12
3
pa
tie
nt
sd
ro
pp
ed
fro
m
th
e
co
m
pe
ns
at
io
n
gr
ou
p
n
/a
n
/a
n
/a
n
/a
Ch
ia
ra
v
al
lo
ti,
D
eL
uc
a,
M
oo
re
&
R
ic
ke
r,
20
05
1
pa
tie
nt
dr
op
pe
d
fro
m
ex
pe
rim
en
ta
lg
ro
up
10
0%
fo
rc
o
n
tr
ol
gr
ou
p
Tr
an
sp
or
ta
tio
n
co
n
st
ra
in
s
0
10
0%
in
bo
th
gr
ou
ps
93
.3
%
fo
re
x
pe
rim
en
ta
l
gr
ou
p
M
en
do
zz
ie
ta
l.,
19
98
n
/a
10
0%
in
bo
th
gr
ou
ps
(as
su
me
d)
n
/a
n
/a
10
0%
in
bo
th
gr
ou
ps
(as
su
me
d)
A
bb
re
v
ia
tio
ns
:n
/a
,n
o
ta
pp
lic
ab
le
du
e
to
da
ta
n
o
tb
ei
ng
av
ai
la
bl
e.
R. Magalha˜es et al. / Are cognitive interventions for Multiple Sclerosis effective and feasible? 633
Our results are not much different from previously pub-
lished studies (das Nair et al., 2012; Rosti-Otajarvi and
Hamalainen, 2011; Thomas et al., 2006). Regarding
longitudinal effects, there are promising findings from
Mattioli, Stampatori et al. (2012) who found improve-
ments of short duration cognitive training to remain
stable at 6 months after the end of the program; and
from another group (Rosti-Otajarvi et al., 2013a) who
displayed positive effects of cognitive intervention on
perceived cognitive deficits that were maintained for
nine months. However, since up to now only few stud-
ies include follow-up assessments, it is still too soon
to assume that (all) cognitive intervention effects can
be maintained afterwards.
The results obtained in the current meta-analysis are
likely to be due to the very limited number of stud-
ies at low risk of bias qualified for inclusion, as well
as the very limited number of domains for the com-
parison (almost no overlapping of outcomes across
studies and few studies per domain). Considering the
positive results of different studies, it seems viable
to hypothesize that availability of only a small num-
ber of high-quality studies in literature, could have
diminished intervention effects, making it impossible
to capture its full capacity. The inclusion of global
cognitive status and an implementation of a standard
cognitive assessment protocol might greatly enhance
findings of the future studies.
Concerning the risk of bias, the allocation conceal-
ment, blinding of participants and personnel as well
as selective reporting, are important issues to be ade-
quately implemented in future studies. It is thus evident
that the field of cognitive rehabilitation in MS is lim-
ited with only few high-quality studies having been
completed up to date. Additionally, as shown before
(Rosti-Otajarvi and Hamalainen, 2011), the overall
quality of cognitive rehabilitation research in MS is
in dire need of improvement. Specific methodological
recommendations to advance the field include:
• An increase in number of participants (the
biggest sample in this meta-analysis was 60
patients, 20 in each group);
• A consensus to implement the same bat-
tery of neuropsychological tests across stud-
ies/worldwide. This procedure would strengthen,
both in number and in quality, the comparisons
between studies in future meta-analysis. In this
regard, BICAMS (Brief International Cognitive
Assessment for Multiple Sclerosis) might pro-
vide a viable option (a worldwide online registry
of a standard neuropsychological battery for MS
patients) (Benedict et al., 2012).
• Assessment of speciﬁc and transfer effects
of progress across intervention sessions, by
documenting tasks and cognitive measures per-
formance for the assessment of abilities trained
during interventions; [Some of the currently avail-
able software provide log files of performance
records (e.g., levels of difficulty, time to comple-
tion) (Vogt et al., 2009)].
• In relation to the previous topic, the implemen-
tation of behavioral and functional outcomes
should be improved as well. Functional or daily
living scales could be used to assess general-
ization of gains to functional/practical aspects
of life [e.g., pegboard tests, Timed Instrumen-
tal Activities of Daily Living (Goverover et al.,
2007; Owsley et al., 2002) visual awareness
tests (Ball et al., 2002)]. Additionally, subjec-
tive measures of cognitive functioning should be
added more consistently across all studies. Even-
tually, if these measures are included, one could
possibly apprehend if improvements in neuropsy-
chological tests would also be accompanied by
amelioration in perceived (subjective) cognitive
functioning. In the study of Rosti-Otajarvi and
coworkers (2013b), for example, improvement
was manifested in (reduced) perceived cognitive
problems reported by the patients.
• Establishment of therapy parameters (e.g., con-
tact with the therapist, duration, and frequency)
is crucial. Without an inclusion of this informa-
tion, it is impossible for readers to understand
the number of needed sessions and the necessary
duration of sessions/programs for effective treat-
ments of cognitive impairments. This issue should
be addressed both for research (NMSS, 2008) as
well as for clinical purposes (NICE, 2003). Evi-
dence regarding this issue is rather scarce (e.g.,
comparison of a highly intensive vs. distributed
training) (Vogt et al., 2009).
• Estimation of costs of the therapeutic
approach. Studies should provide costs of inter-
vention (including therapists’ salary, materials,
software and manuals), calculated per session
and per program. These data are fundamental for
policy makers/governmental entities in deciding
if these approaches are cost-effective and can be
made available to patients (NICE, 2003).
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• Use of Web-based interventions for the efficient
registration of outcomes so they can be compared
with more traditional paper-and-pencil interven-
tions, particularly in terms of costs.
Thus, many questions, pertaining to the efficacy
of cognitive intervention, remain to be answered,
mainly due to methodological questions. However,
the present results must be interpreted cautiously.
Importantly, “a lack of evidence; however, does not
equate to evidence against a procedure” (Freeman
and Playford, 2012). Factors that may contribute to
the lack of consistent evidence across studies should
be acknowledged: 1) Neuropsychological tests might
not be sensitive to subtle gains from the cogni-
tive intervention, despite the implemented cognitive
approach. For instance, even though patients might
feel less burdened with cognitive slowing and use
more internal strategies to cope with memory impair-
ments neuropsychological tests might not capture these
changes. 2) Statistical significance is typically over-
valued and few acknowledge the importance of a
clinically meaningful change that may result from
cognitive intervention. Benedict and Walton (2012)
have recently drawn attention to this issue, referring
to the use of patient-reported outcomes (PROs) and of
clinically meaningful change in MS studies. Namely,
Food and Drug Administration (FDA) Guidance high-
lights that, besides providing statistical evidence of a
given treatment, one should also examine the pres-
ence of individual meaningful change (Benedict and
Walton, 2012). Additionally, one should also account
for the “amount of change that has actual meaning to
a patient’s daily life” (Benedict and Walton, 2012)
and might not be measured by neuropsychological
tests. Determining what is a clinically meaningful
change for primary outcomes in clinical trials and the
development of outcome measures tackling patient’
experience and goals, could be a noteworthy path to
follow. For example, Morrow and colleagues (2010)
verified that a decline of four points in Symbol Digit
Modalities Test (Smith, 1982) could distinguish MS
patients in terms of employment status. Could this
value be used as a criterion for determining efficacy
of given cognitive treatment? This question remains to
be explored.
Another issue is the duration and intensity of inter-
ventions. According to Shatil and colleagues (2010),
several cognitive interventions need a longer duration
to yield tangible results. Thus, for brain reorganiza-
tion to occur, or new strategies learned, one would
have to undergo more treatment to maximize the ther-
apeutic benefits. The above-mentioned group (Shatil
et al., 2010) showed that an intensive (3 sessions per
week for 12-weeks) home-based cognitive intervention
could be effective in improving memory and process-
ing speed. Of note, the longest intervention included
in our meta-analysis comprised of 15 sessions (twice
a week), shorter and less intensive than the schedule
proposed by Shatil and colleagues (2010) which might
explain the lack of affirmative results in the present
meta-analysis.
Additionally, feasibility of cognitive interventions is
seldom reported. So far, there is only adherence data
from a home-based cognitive training program (Shatil
et al., 2010), with 57.6% of the participants complet-
ing more than half of the prescribed sessions of the
cognitive intervention program at home (unprompted
and with no reminders). Our feasibility analysis of
cognitive interventions, however, yielded good com-
pletion and adherence rates (ranging between 92.3%
and 100%; and 100% respectively).
Another important issue is the personalization of
cognitive training for each patient. Such personal-
ization requires that the patient’s baseline cognitive
assessment to be the starting point for determining
areas in need of improvement. Concerning tailor-
made interventions, some authors (Shatil et al., 2010;
Vogt et al., 2009) used an interactive-adaptive sys-
tem to continually adapt to the level of difficulty of
the patient’s performance. These are some important
aspects to be taken into consideration when design-
ing future cognitive intervention trials. It should also
be further investigated, whether cognitive interven-
tion could complement pharmaceutical interventions
for delaying or decreasing Multiple Sclerosis-related
cognitive impairments. Considering the fact that com-
bination of different approaches could yield far
more potential than a single treatment used in iso-
lation (Goverover et al., 2011; NICE, 2003), it is
very relevant to evaluate the combined clinical rele-
vance of different interventions. For example, there
is evidence of the beneficial impact of physical
fitness on the cognition of MS patients (Sandroff
et al., 2014) and on neurogenesis and hippocam-
pal function in elderly (Erickson et al., 2011). Some
authors argue that combined interventions (i.e. cog-
nitive plus physical training) might be the most
effective approach in preventing cognitive decline
(Oswald et al., 2006). RCTs using cognitive training
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in combination with physical exercise in MS popula-
tions are warranted (Motl et al., 2011). Nevertheless,
the compared value of individual and combined
approaches as brain health promoting therapies needs
further evidence for the establishment of firm conclu-
sions.
Finally, it is also important to explore those who
benefit most from cognitive interventions, as well
as the common factors that may underlie the poten-
tial improvements. Factors such as cognitive reserve
(Stern, 2002), education (Scarpazza et al., 2013), the
existence of cognitive impairment and employment
status are known to mediate cognitive functioning
in MS (Strober et al., 2013; Sumowski et al., 2013;
Sumowski et al., 2010). Hence, post-hoc analysis in
clinical trials might be helpful in identifying indi-
vidual differences that may account for variability in
response to treatments. In the same line of thought,
it is also important to provide cognitive intervention
only to patients who have clearly demonstrated cog-
nitive impairments, since these are the ones who are
more likely to benefit (Chiaravalloti et al., 2005; Rosti-
Otajarvi et al., 2013b).
Regarding study limitations the present meta-
analysis is constrained by the utilized strict criteria
in selecting only RCTs, which resulted in few stud-
ies being included in meta-analysis. Methodological
limitations, such as comparing groups under different
conditions, found in several studies, prevented us from
comparing more results.
5. Conclusion
Multiple Sclerosis disease entails numerous impli-
cations. For instance, inability to sustain employment
(Grima et al., 2000), decline in Quality of Life (Kobelt
et al., 2006), early-retiring patients with high levels
of dependence from informal care, add up to be quite
costly. Considering that brain plasticity has been shown
to occur throughout lifespan (Landi and Rossini, 2010)
and “is the most efficient way to preserve brain func-
tion despite progressive loss of structural resources”
(Scarpazza et al., 2013), cognitive intervention is con-
sidered a worthwhile option for managing cognitive
impairments in MS. For further development and opti-
mization of this approach, an additional investment
of time and resources in the cognitive rehabilitation
field, particularly in this clinical group, is still in much
demand.
In the present study, although cognitive interven-
tion presents good adherence and completion rates,
feasibility and cost-effectiveness are in need for fur-
ther exploration as it has been recently recommended
for other neurodegenerative pathologies such as in
Alzheimer’s disease (Alves et al., 2013). To create
practice guidelines, cognitive intervention parame-
ters, such as optimal duration and intensity of those
interventions should be established as well. Future
clinical trials should work on improving method-
ological concerns, such as allocation, concealment,
blinding of participants and personnel, to facilitate
the establishment of cognitive intervention efficacy in
MS.
Acknowledgments
R.M. and J.A. are supported by doctoral Grants
from Fundac¸a˜o para a Cieˆncia e Tecnologia (FCT)
(SFRH/BD/65213/2009, SFRH/BD/64457/2009 and
co-funded by FSE/POPH). A.S. is funded for the
project PIC/IC/83290/2007, supported by FEDER
(POFC–COMPETE) and FCT to develop and assess
the effectiveness of a cognitive stimulation tool for
Portuguese clinicians.
References
Alves, J., Magalhaes, R., Thomas, R.E., Goncalves, O.F., Petrosyan,
A., & Sampaio, A. (2013). Is there evidence for cognitive
intervention in Alzheimer disease? A systematic review of effi-
cacy, feasibility, and cost-effectiveness. Alzheimer Dis Assoc
Disord, 27(3), 195-203.
Amato, M.P., Langdon, D., Montalban, X., Benedict, R.H., Deluca,
J., Krupp, L.B., et al., (2013). Treatment of cognitive impair-
ment in multiple sclerosis: Position paper. J Neurol, 260(6),
1452-1468.
Amato, M.P., Ponziani, G., Siracusa, G., & Sorbi, S. (2001). Cogni-
tive dysfunction in early-onset multiple sclerosis: A reappraisal
after 10 years. Arch Neurol, 58(10), 1602-1606.
Ball, K., Berch, D.B., Helmers, K.F., Jobe, J.B., Leveck, M.D.,
Marsiske, M., et al. (2002). Effects of cognitive training inter-
ventions with older adults: A randomized controlled trial.
JAMA, 288(18), 2271-2281.
Benedict, R.H., Amato, M.P., Boringa, J., Brochet, B.,
Foley, F., Fredrikson, S., et al. (2012). Brief Inter-
national Cognitive Assessment for MS (BICAMS):
International standards for validation. BMC Neurol, 12,
55.
Benedict, R.H., Cookfair, D., Gavett, R., Gunther, M., Munschauer,
F., Garg, N., & Weinstock-Guttman, B. (2006). Validity of the
636 R. Magalha˜es et al. / Are cognitive interventions for Multiple Sclerosis effective and feasible?
minimal assessment of cognitive function in multiple sclerosis
(MACFIMS). J Int Neuropsychol Soc, 12(4), 549-558.
Benedict, R.H., & Walton, M.K. (2012). Evaluating cognitive out-
come measures for MS clinical trials: What is a clinically
meaningful change? Mult Scler, 18(12), 1673-1679.
Brassington, J.C., & Marsh, N.V. (1998). Neuropsychologi-
cal aspects of multiple sclerosis. Neuropsychol Rev, 8(2),
43-77.
Brenk, A., Laun, K., & Haase, C.G. (2008). Short-term cognitive
training improves mental efficiency and mood in patients with
multiple sclerosis. Eur Neurol, 60(6), 304-309.
Brissart, H., Leroy, M., & Debouverie, M. (2010). Cognitive rehabili-
tation in multiple sclerosis: Preliminary results and presentation
of a new program, PROCOG-SEP. Rev Neurol (Paris), 166(4),
406-411.
Cerasa, A., Gioia, M.C., Valentino, P., Nistico, R., Chiriaco, C.,
Pirritano, D., et al. (2013). Computer-assisted cognitive rehabil-
itation of attention deficits for multiple sclerosis: A randomized
trial with FMRI correlates. Neurorehabil Neural Repair, 27(4),
284-295.
Chiaravalloti, N.D., & DeLuca, J. (2008). Cognitive impairment in
multiple sclerosis. Lancet Neurol, 7(12), 1139-1151.
Chiaravalloti, N.D., DeLuca, J., Moore, N.B., & Ricker, J.H. (2005).
Treating learning impairments improves memory performance
in multiple sclerosis: A randomized clinical trial. Mult Scler,
11(1), 58-68.
Chiaravalloti, N.D., Stojanovic-Radic, J., & Deluca, J. (2013). The
role of speed versus working memory in predicting learning
new information in multiple sclerosis. JClin ExpNeuropsychol,
35(2), 180-191.
Chiaravalloti, N.D., Wylie, G., Leavitt, V., & Deluca, J. (2012).
Increased cerebral activation after behavioral treatment for
memory deficits in MS. J Neurol, 259(7), 1337-1346.
das Nair, R., Ferguson, H., Stark, D.L., & Lincoln, N.B. (2012).
Memory Rehabilitation for people with multiple sclerosis.
Cochrane Database Syst Rev 3, CD008754.
das Nair, R., & Lincoln, N.B. (2012). Evaluation of rehabilitation of
memory in neurological disabilities (ReMiND): A randomized
controlled trial. Clin Rehabil, 26(10), 894-903.
DeLuca, J. (2006). What We Know about Cognitive Changes in
Multiple Sclerosis. In: N. LaRocca & R. Kalb (Eds.), Multiple
Sclerosis: Understanding the cognitive challenges (pp. 17-39).
New York: Demos Medical Publishing.
DeLuca, J., Barbieri-Berger, S., & Johnson, S.K. (1994). The nature
of memory impairments in multiple sclerosis: Acquisition ver-
sus retrieval. J Clin Exp Neuropsychol, 16(2), 183-189.
DeLuca, J., Chelune, G.J., Tulsky, D.S., Lengenfelder, J., & Chiar-
avalloti, N.D. (2004). Is speed of processing or working
memory the primary information processing deficit in multiple
sclerosis? J Clin Exp Neuropsychol, 26(4), 550-562.
Erickson, K.I., Voss, M.W., Prakash, R.S., Basak, C., Szabo, A.,
Chaddock, L., et al. (2011). Exercise training increases size of
hippocampus and improves memory. Proc Natl Acad Sci U S
A, 108(7), 3017-3022.
Fink, F., Rischkau, E., Butt, M., Klein, J., Eling, P., & Hildebrandt,
H. (2010). Efficacy of an executive function intervention pro-
gramme in MS: A placebo-controlled and pseudo-randomized
trial. Mult Scler, 16(9), 1148-1151.
Freeman, J.A., & Playford, E.D. (2012). Rehabilitation therapy in
MS; a short-term, expensive, placebo. Mult Scler, 18(10), 1379-
1381.
Goverover, Y., Basso, M., Wood, H., Chiaravalloti, N., & DeLuca,
J. (2011). Examining the benefits of combining two learning
strategies on recall of functional information in persons with
multiple sclerosis. Mult Scler, 17(12), 1488-1497.
Goverover, Y., Genova, H.M., Hillary, F.G., & DeLuca, J. (2007).
The relationship between neuropsychological measures and the
Timed Instrumental Activities of Daily Living task in multiple
sclerosis. Mult Scler, 13(5), 636-644.
Grima, D.T., Torrance, G.W., Francis, G., Rice, G., Rosner, A.J.,
& Lafortune, L. (2000). Cost and health related quality of life
consequences of multiple sclerosis. Mult Scler, 6(2), 91-98.
He, D., Zhou, H., Guo, D., Hao, Z., & Wu, B. (2011). Pharmacologic
treatment for memory disorder in multiple sclerosis. Cochrane
Database Syst Rev (10), CD008876.
Higgins, J.P., Thompson, S.G., Deeks, J.J., & Altman, D.G. (2003).
Measuring inconsistency in meta-analyses. BMJ, 327(7414),
557-560.
Hildebrandt, H., Lanz, M., Hahn, H.K., Hoffmann, E., Schwarze, B.,
Schwendemann, G., & Kraus, J.A. (2007). Cognitive training
in MS: Effects and relation to brain atrophy. Restor Neurol
Neurosci, 25(1), 33-43.
Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S., & Jonsson, B.
(2006). Costs and quality of life of patients with multiple
sclerosis in Europe. J Neurol Neurosurg Psychiatry, 77(8),
918-926.
Krupp, L.B., Christodoulou, C., Melville, P., Scherl, W.F., MacAllis-
ter, W.S., & Elkins, L.E. (2004). Donepezil improved memory
in multiple sclerosis in a randomized clinical trial. Neurology,
63(9), 1579-1585.
Krupp, L.B., Christodoulou, C., Melville, P., Scherl, W.F., Pai, L.Y.,
Muenz, L.R., et al. (2011). Multicenter randomized clinical
trial of donepezil for memory impairment in multiple sclerosis.
Neurology, 76(17), 1500-1507.
Landi, D., & Rossini, P.M. (2010). Cerebral restorative plasticity
from normal ageing to brain diseases: A “never ending story".
Restor Neurol Neurosci, 28(3), 349-366.
Lincoln, N.B., Dent, A., Harding, J., Weyman, N., Nicholl, C.,
Blumhardt, L.D., & Playford, E.D. (2002). Evaluation of cog-
nitive assessment and cognitive intervention for people with
multiple sclerosis. J Neurol Neurosurg Psychiatry, 72(1), 93-
98.
Lustig, C., Shah, P., Seidler, R., & Reuter-Lorenz, P.A. (2009).
Aging, training, and the brain: A review and future directions.
Neuropsychol Rev, 19(4), 504-522.
Mattioli, F., Stampatori, C., Scarpazza, C., Parrinello, G., & Capra,
R. (2012). Persistence of the effects of attention and executive
functions intensive rehabilitation in relapsing remitting multi-
ple sclerosis. Multiple Sclerosis and Related Disorders, 1(4),
168-173.
Mattioli, F., Stampatori, C., Zanotti, D., Parrinello, G., & Capra,
R. (2010). Efficacy and specificity of intensive cognitive
R. Magalha˜es et al. / Are cognitive interventions for Multiple Sclerosis effective and feasible? 637
rehabilitation of attention and executive functions in multiple
sclerosis. J Neurol Sci, 288(1-2), 101-105.
McCarthy, M., Beaumont, J.G., Thompson, R., & Peacock, S.
(2005). Modality-specific aspects of sustained and divided
attentional performance in multiple sclerosis. Arch Clin Neu-
ropsychol, 20(6), 705-718.
Mendozzi, L., Pugnetti, L., Motta, A., Barbieri, E., Gambini, A., &
Cazzullo, C.L. (1998). Computer-assisted memory retraining
of patients with multiple sclerosis. Ital J Neurol Sci, 19, S431-
S438.
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D.G. (2009).
Preferred reporting items for systematic reviews and meta-
analyses: The PRISMA statement. PLoS Med, 6(7), e1000097.
Morrow, S.A., Drake, A., Zivadinov, R., Munschauer, F., Weinstock-
Guttman, B., & Benedict, R.H. (2010). Predicting loss of
employment over three years in multiple sclerosis: Clinically
meaningful cognitive decline. Clin Neuropsychol, 24(7), 1131-
1145.
Morrow, S.A., Kaushik, T., Zarevics, P., Erlanger, D., Bear, M.F.,
Munschauer, F.E., & Benedict, R.H. (2009). The effects of L-
amphetamine sulfate on cognition in MS patients: Results of a
randomized controlled trial. J Neurol, 256(7), 1095-1102.
Moss-Morris, R., McCrone, P., Yardley, L., van Kessel, K., Wills, G.,
& Dennison, L. (2012). A pilot randomised controlled trial of an
Internet-based cognitive behavioural therapy self-management
programme (MS Invigor8) for multiple sclerosis fatigue. Behav
Res Ther, 50(6), 415-421.
Motl, R.W., Sandroff, B.M., & Benedict, R.H. (2011). Cognitive
dysfunction and multiple sclerosis: Developing a rationale for
considering the efficacy of exercise training. Mult Scler, 17(9),
1034-1040.
NICE. (2003). Management of MS in primary and secondary care.
Clinical guideline 8. London: National Institute for Clinical
Excellence.
NMSS. (2008). Assessment and Management of Cognitive
Impairment in Multiple Sclerosis. Treatment Recommen-
dations for Physicians. Retrieved July 6, 2013, from
http://www.nationalmssociety.org/
O’Brien, A.R., Chiaravalloti, N., Goverover, Y., & Deluca, J. (2008).
Evidenced-based cognitive rehabilitation for persons with mul-
tiple sclerosis: A review of the literature. Arch Phys Med
Rehabil, 89(4), 761-769.
Oswald, W.D., Gunzelmann, T., Rupprecht, R., & Hagen, B. (2006).
Differential effects of single versus combined cognitive and
physical training with older adults: The SimA study in a 5-year
perspective. European Journal of Ageing, 3(4), 179-192.
Owsley, C., Sloane, M., McGwin, G., Jr., & Ball, K. (2002). Timed
instrumental activities of daily living tasks: Relationship to cog-
nitive function and everyday performance assessments in older
adults. Gerontology, 48(4), 254-265.
Rao, S.M., Grafman, J., DiGiulio, D., Mittenberg, W., Bernardin,
L., Leo, G.J., et al. (1993). Memory dysfunction in multiple
sclerosis: Its relation to working memory, semantic encoding,
and implicit learning. Neuropsychology, 7, 364-374.
Rao, S.M., Leo, G.J., Bernardin, L., & Unverzagt, F. (1991). Cog-
nitive dysfunction in multiple sclerosis. I. Frequency, patterns,
and prediction. Neurology, 41(5), 685-691.
RevMan. (2012). Review Manager (RevMan) [Computer program]
(Version Version 5.2.3). Copenhagen: The Nordic Cochrane
Centre: The Cochrane Collaboration.
Rosti-Otajarvi, E.M., & Hamalainen, P.I. (2011). Neuropsycholog-
ical rehabilitation for multiple sclerosis. Cochrane Database
Syst Rev (11), CD009131.
Rosti-Otajarvi, E.M., Mantynen, A., Koivisto, K., Huhtala, H., &
Hamalainen, P. (2013a). Neuropsychological rehabilitation has
beneficial effects on perceived cognitive deficits in multiple
sclerosis during nine-month follow-up. J Neurol Sci, 334(1-2),
154-160.
Rosti-Otajarvi, E.M., Mantynen, A., Koivisto, K., Huhtala, H., &
Hamalainen, P. (2013b). Patient-related factors may affect the
outcome of neuropsychological rehabilitation in multiple scle-
rosis. J Neurol Sci, 334(1-2), 106-111.
Sandroff, B.M., Klaren, R.E., Pilutti, L.A., Dlugonski, D., Bene-
dict, R.H., & Motl, R.W. (2014). Randomized controlled trial of
physical activity, cognition, and walking in multiple sclerosis.
J Neurol, 261(2), 363-372.
Scarpazza, C., Braghittoni, D., Casale, B., Malagu, S., Mattioli, F.,
di Pellegrino, G., & Ladavas, E. (2013). Education protects
against cognitive changes associated with multiple sclerosis.
Restor Neurol Neurosci, 31(5), 619-631.
Shatil, E., Metzer, A., Horvitz, O., & Miller, A. (2010). Home-
based personalized cognitive training in MS patients: A study
of adherence and cognitive performance. NeuroRehabilitation,
26(2), 143-153.
Smith, A. (1982). Symbol Digit Modality Test, Western Psychologi-
cal Services, Los Angeles, CA.
Solari, A., Motta, A., Mendozzi, L., Pucci, E., Forni, M., Man-
cardi, G., & Pozzilli, C. (2004). Computer-aided retraining of
memory and attention in people with multiple sclerosis: A ran-
domized, double-blind controlled trial. J Neurol Sci, 222(1-2),
99-104.
Stern, Y. (2002). What is cognitive reserve? Theory and research
application of the reserve concept. J Int Neuropsychol Soc, 8(3),
448-460.
Strober, L., Chiaravalloti, N., Moore, N., & Deluca, J. (2013).
Unemployment in multiple sclerosis (MS): Utility of the MS
Functional Composite and cognitive testing. Mult Scler.
Stuifbergen, A.K., Becker, H., Perez, F., Morison, J., Kullberg, V., &
Todd, A. (2012). A randomized controlled trial of a cognitive
rehabilitation intervention for persons with multiple sclerosis.
Clin Rehabil, 26(10), 882-893.
Sumowski, J.F., Chiaravalloti, N., Erlanger, D., Kaushik, T., Bene-
dict, R.H., & DeLuca, J. (2011). L-amphetamine improves
memory in MS patients with objective memory impairment.
Mult Scler, 17(9), 1141-1145.
Sumowski, J.F., Rocca, M.A., Leavitt, V.M., Riccitelli, G., Comi, G.,
Deluca, J., & Filippi, M. (2013). Brain reserve and cognitive
reserve in multiple sclerosis: What you’ve got and how you use
it. Neurology, 80(24), 2186-2193.
Sumowski, J.F., Wylie, G.R., Deluca, J., & Chiaravalloti, N.
(2010). Intellectual enrichment is linked to cerebral effi-
ciency in multiple sclerosis: Functional magnetic resonance
imaging evidence for cognitive reserve. Brain, 133(Pt 2),
362-374.
638 R. Magalha˜es et al. / Are cognitive interventions for Multiple Sclerosis effective and feasible?
Tesar, N., Bandion, K., & Baumhackl, U. (2005). Efficacy of a neu-
ropsychological training programme for patients with multiple
sclerosis – a randomised controlled trial.WienKlinWochenschr,
117(21-22), 747-754.
Thomas, P.W., Thomas, S., Hillier, C., Galvin, K., & Baker,
R. (2006). Psychological interventions for multiple sclerosis.
Cochrane Database Syst Rev (1), CD004431.
Vogt, A., Kappos, L., Calabrese, P., Stocklin, M., Gschwind, L.,
Opwis, K., & Penner, I.K. (2009). Working memory training in
patients with multiple sclerosis - comparison of two different
training schedules. Restor Neurol Neurosci, 27(3), 225-235.
